Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

12 Jan 2017

Abstract excerpt

p53-related protein kinase (TP53RK, also known as PRPK) is an upstream kinase that phosphorylates (serine residue Ser15) and mediates p53 activity. Here we show that TP53RK confers poor prognosis in multiple myeloma (MM) patients, and, conversely, that TP53RK knockdown inhibits p53 phosphorylation and triggers MM cell apoptosis, associated with downregulation of c-Myc and E2F-1-mediated upregulation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28082445
DOI: 10.1182/blood-2016-09-738500

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaPMID 28082445Read ↗

Deregulation and Targeting of TP53 Pathway in Multiple MyelomaSemantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.Semantic proximity Read ↗

Multi-omic and functional screening reveal targetable vulnerabilities in<i>TP53</i>mutated multiple myelomaSemantic proximity Read ↗

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.Semantic proximity Read ↗

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair InhibitorsSemantic proximity Read ↗

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.Semantic proximity Read ↗

Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted<i>TP53</i>Semantic proximity Read ↗

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaSemantic proximity Read ↗

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic ResponsesSemantic proximity Read ↗

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.